The Who, What and Wow of Anti-Obesity Medications (for cardiologists)-The Who, What and Wow of Anti-Obesity Medications (for cardiologists)

The Who, What and Wow of Anti-Obesity Medications (for cardiologists)

Video Transcription

Video Summary

In this video, Dr. Sheldon Litwin discusses the new developments in the use of anti-obesity medications, particularly their use by cardiologists. He highlights the increasing prevalence of obesity and its impact on cardiovascular diseases such as heart failure. Dr. Litwin emphasizes that weight loss is achievable through various means including bariatric surgery, lifestyle changes, and the use of pharmacological interventions. He discusses the effectiveness of medications such as fentramine-topiramate and GLP-1 agonists in achieving weight loss of up to 13-22% and their cardiovascular benefits. Dr. Litwin highlights the underuse of these medications, citing reasons such as lack of familiarity, cost issues, and the perception that obesity is a personal failure. He encourages cardiologists to embrace their role in diagnosing, discussing, and treating obesity and to become comfortable with prescribing weight loss medications. Dr. Litwin also mentions ongoing trials and the pipeline of new drugs in development for weight loss and its impact on cardiovascular outcomes.

Keywords

anti-obesity medications

cardiologists

obesity

weight loss

cardiovascular diseases

pharmacological interventions